User profiles for P. Paoletti
Pierre PaolettiEcole Normale Supérieure, INSERM, CNRS, Université PSL Verified email at ens.fr Cited by 12965 |
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
P Paoletti, C Bellone, Q Zhou - Nature Reviews Neuroscience, 2013 - nature.com
NMDA receptors (NMDARs) are glutamate-gated ion channels and are crucial for neuronal
communication. NMDARs form tetrameric complexes that consist of several homologous …
communication. NMDARs form tetrameric complexes that consist of several homologous …
NMDA receptor subunits: function and pharmacology
P Paoletti, J Neyton - Current opinion in pharmacology, 2007 - Elsevier
… Recently, however, Hatton and Paoletti [40 • ] have been able to overcome this difficulty
and isolate recombinant triheteromeric receptors using an approach combining mutagenesis …
and isolate recombinant triheteromeric receptors using an approach combining mutagenesis …
Zinc in the physiology and pathology of the CNS
The past few years have witnessed dramatic progress on all frontiers of zinc neurobiology.
The recent development of powerful tools, including zinc-sensitive fluorescent probes, …
The recent development of powerful tools, including zinc-sensitive fluorescent probes, …
Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy
…, Shaharyar, C Manegold, S Paul, P Paoletti… - Journal of clinical …, 2004 - ascopubs.org
… In this study, patients treated with pemetrexed had a significantly lower rate of alopecia (P
< .001) and a trend toward lower rates of grade 3 or 4 diarrhea (P = .069) compared with …
< .001) and a trend toward lower rates of grade 3 or 4 diarrhea (P = .069) compared with …
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
…, S Emri, C Manegold, C Niyikiza, P Paoletti - Journal of clinical …, 2003 - ascopubs.org
… Median survival time in the pemetrexed/cisplatin arm was 12.1 months versus 9.3 months
in the control arm (P = .020, two-sided log-rank test). The hazard ratio for death of patients in …
in the control arm (P = .020, two-sided log-rank test). The hazard ratio for death of patients in …
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force
…, P Vermeire, NB Pride, P Paoletti… - European …, 1995 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by reduced
maximum expiratory flow and slow forced emptying of the lungs; features which do not change …
maximum expiratory flow and slow forced emptying of the lungs; features which do not change …
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on …
…, B Newstat, D Roychowdhury, P Paoletti… - Breast cancer research …, 2008 - Springer
… In the continuous variable model, higher HER2 ECD was associated with a shorter PFS (P
< 0.001) in the capecitabine group, but not in the combination-therapy group (P = 0.12). Given …
< 0.001) in the capecitabine group, but not in the combination-therapy group (P = 0.12). Given …
High-affinity zinc inhibition of NMDA NR1–NR2A receptors
P Paoletti, P Ascher, J Neyton - Journal of Neuroscience, 1997 - Soc Neuroscience
Micromolar concentrations of extracellular Zn 2+ are known to antagonize native NMDA
receptors via a dual mechanism involving both a voltage-independent and a voltage-dependent …
receptors via a dual mechanism involving both a voltage-independent and a voltage-dependent …
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
…, D Zembryki, C Oliva, D Roychowdhury, P Paoletti… - Clinical cancer …, 2009 - AACR
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast
cancer. Effective therapy for patients with central nervous system (CNS) progression after …
cancer. Effective therapy for patients with central nervous system (CNS) progression after …
Zinc at glutamatergic synapses
P Paoletti, AM Vergnano, B Barbour, M Casado - Neuroscience, 2009 - Elsevier
It has long been known that the mammalian forebrain contains a subset of glutamatergic
neurons that sequester zinc in their synaptic vesicles. This zinc may be released into the …
neurons that sequester zinc in their synaptic vesicles. This zinc may be released into the …